Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2016

View Archived Issues

FDA grants orphan drug designation to ONC-201

BeiGene's BTK inhibitor granted U.S. orphan status for lymphomas

Allakos initiates phase I trial of AK-002 in indolent systemic mastocytosis

Quantum Genomics initiates phase IIa trial of QGC-101 for heart failure

Results from a phase I trial with autologous MSCNPs in MS patients

Epiduo approved in Japan

Merck & Co. patents ERK inhibitors

Roche and Genentech report retinoid RORgamma ligands

OncoArendi Therapeutics discloses acidic mammalian chitinase inhibitors

Estrogen receptor alpha ligands described in Roche and Genentech patent

PharmNovo patents delta-opioid receptor agonists

Phase III study of NK-105 does not meet the primary endpoint

Preliminary results reported for nivolumab in colon, pancreatic and anal cancer

AstraZeneca initiates first-in-human trial of AZD-4635 in advanced solid tumors

Topline results reported from Japanese phase III study of AnGes' NF-kappaB decoy oligo

ZEB1 shows promise as a diagnostic biomarker for GEA

Targovax begins dosing in phase Ib/II trial of ONCOS-102

Sanofi Pasteur signs CRADA with WRAIR on Zika vaccine candidate

Biocryst Pharmaceuticals receives NIAID funding

Zinbryta approved in European Union for treatment of multiple sclerosis

IKAROS may be useful as a prognostic biomarker in PADC

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals and gains full rights to HuMax-IL8

FDA approves InSys Therapeutic's Syndros

FDA awards fast track designation to Scenesse for erythropoietic protoporphyria

Ophtalix releases phase II results for CF-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...